Assessing the immediate impact of COVID-19 on surgical oncology practice: Experience from an NCI-designated Comprehensive Cancer Center in the Northeastern United States.
COVID-19
/ complications
Cancer Care Facilities
/ standards
Female
Follow-Up Studies
Humans
Male
Middle Aged
National Cancer Institute (U.S.)
Neoplasms
/ pathology
New England
/ epidemiology
Practice Patterns, Physicians'
/ statistics & numerical data
Retrospective Studies
SARS-CoV-2
/ isolation & purification
Surgical Oncology
/ statistics & numerical data
Telemedicine
/ statistics & numerical data
United States
COVID-19
clinic volume
operative volume
pandemic
telehealth
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
11
03
2021
accepted:
14
03
2021
pubmed:
26
3
2021
medline:
22
6
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
The effects of the coronavirus disease 2019 (COVID-19) pandemic on surgical oncology practice are not yet quantified. The aim of this study was to measure the immediate impact of COVID-19 on surgical oncology practice volume. A retrospective study of patients treated at an NCI-Comprehensive Cancer Center was performed. "Pre-COVID" era was defined as January-February 2020 and "COVID" as March-April 2020. Primary outcomes were clinic visits and operative volume by surgical oncology subspecialty. Abouyt 907 new patient visits, 3897 follow-up visits, and 644 operations occurred during the study period. All subspecialties experienced significant decreases in new patient visits during COVID, though soft tissue oncology (Mel/Sarc), gynecologic oncology (Gyn/Onc), and endocrine were disproportionately affected. Telehealth visits increased to 11.4% of all visits by April. Mel/Sarc, Gyn/Onc, and Breast experienced significant operative volume decreases during COVID (25.8%, p = 0.012, 43.6% p < 0.001, and 41.9%, p < 0.001, respectively), while endocrine had no change and gastrointestinal oncology had a slight increase (p = 0.823) in the number of cases performed. The effects of the COVID-19 pandemic are wide-ranging within surgical oncology subspecialties. The addition of telehealth is a viable avenue for cancer patient care and should be considered in surgical oncology practice.
Sections du résumé
BACKGROUND
BACKGROUND
The effects of the coronavirus disease 2019 (COVID-19) pandemic on surgical oncology practice are not yet quantified. The aim of this study was to measure the immediate impact of COVID-19 on surgical oncology practice volume.
METHODS
METHODS
A retrospective study of patients treated at an NCI-Comprehensive Cancer Center was performed. "Pre-COVID" era was defined as January-February 2020 and "COVID" as March-April 2020. Primary outcomes were clinic visits and operative volume by surgical oncology subspecialty.
RESULTS
RESULTS
Abouyt 907 new patient visits, 3897 follow-up visits, and 644 operations occurred during the study period. All subspecialties experienced significant decreases in new patient visits during COVID, though soft tissue oncology (Mel/Sarc), gynecologic oncology (Gyn/Onc), and endocrine were disproportionately affected. Telehealth visits increased to 11.4% of all visits by April. Mel/Sarc, Gyn/Onc, and Breast experienced significant operative volume decreases during COVID (25.8%, p = 0.012, 43.6% p < 0.001, and 41.9%, p < 0.001, respectively), while endocrine had no change and gastrointestinal oncology had a slight increase (p = 0.823) in the number of cases performed.
CONCLUSIONS
CONCLUSIONS
The effects of the COVID-19 pandemic are wide-ranging within surgical oncology subspecialties. The addition of telehealth is a viable avenue for cancer patient care and should be considered in surgical oncology practice.
Identifiants
pubmed: 33765341
doi: 10.1002/jso.26475
pmc: PMC8250700
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-15Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Cancer. 2020 Oct 15;126(20):4466-4472
pubmed: 32749697
J Thorac Cardiovasc Surg. 2020 Aug;160(2):601-605
pubmed: 32689703
Head Neck. 2020 Jun;42(6):1179-1186
pubmed: 32459061
Ann Surg. 2019 Sep;270(3):564-572
pubmed: 31356267
J Gastrointest Surg. 2020 Jul;24(7):1692-1697
pubmed: 32385614
Breast Cancer Res Treat. 2020 Jun;181(3):487-497
pubmed: 32333293
J Am Coll Surg. 2016 May;222(5):915-27
pubmed: 27016900
Br J Surg. 2019 Sep;106(10):1311-1318
pubmed: 31216065
Am J Surg. 2019 Sep;218(3):476-479
pubmed: 30253859
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JCO Clin Cancer Inform. 2020 Nov;4:1059-1071
pubmed: 33253013
J Surg Oncol. 2020 Jun 2;:
pubmed: 32488866
J Surg Oncol. 2021 Jul;124(1):7-15
pubmed: 33765341
Gynecol Oncol. 2020 Aug;158(2):256-261
pubmed: 32482336
Head Neck. 2020 Jul;42(7):1471-1476
pubmed: 32427410
Am J Clin Oncol. 2020 Oct;43(10):679-684
pubmed: 32852291
Gynecol Oncol. 2020 Nov;159(2):470-475
pubmed: 32981694
JAMA Netw Open. 2020 Aug 3;3(8):e2017267
pubmed: 32749465
Surg Clin North Am. 2021 Feb;101(1):109-119
pubmed: 33212072
Ann Surg Oncol. 2020 Jun;27(6):1717-1720
pubmed: 32270420